FibroBiologics seeks US FDA patent for generation of three-dimensional organoids using fibroblast cell-based technology: Houston Saturday, September 14, 2024, 17:00 Hrs [IST] Fibr ...

The leading biopharmaceutical company is focused on developing and commercializing fibroblast cell-based therapies.

Imagine trying to poke a hole in the yolk of a raw egg without breaking the egg white. It sounds impossible, but researchers ...

AVITA's large addressable market, high gross margins, and low valuation suggest the potential for 154% stock upside. Find out ...

Event: 2024 Cell & Gene Meeting on the Mesa Session Date and Time: October 7, 2024, at 5:45 p.m. MST Location: FLW Ballroom F For more information, please visit FibroBiologics' website or email ...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company announced today that its LEGION Hinged Knee (HK) ...

As people age, more patients are developing heart failure. A study from Nagoya University found that an enzyme called PKN is ...

suggests that transforming growth factor β (TGF-β) and platelet-derived growth factor (PDGF) act synergistically to direct synovial fibroblasts toward a more aggressive phenotype in response to ...

Our research focuses on the tumor-permissive molecular mechanisms underlying cancer-associated fibroblast function as well as immune suppression, and how these stromal mechanisms affect cell fate and ...

“This patent, if issued, will allow us to pursue the development of a versatile ... and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials.